The Etiologic Role of Infectious Antigens in Sarcoidosis Pathogenesis

Lindsay J. Celada, PhD[a], Charlene Hawkins, PhD[b],
Wonder P. Drake, PhD[a,b],*

KEYWORDS

- Sarcoidosis - Antimicrobials - Infectious antigens

KEY POINTS

- There is a growing body of literature supporting the role of infectious antigens, in particular mycobacteria and propionibacteria, in sarcoidosis pathogenesis.
- Immunologic studies reveal that mycobacterial virulence factors are the targets of the immune response in sarcoidosis diagnostic bronchoalveolar lavage (BAL).
- Recently, case reports and clinical trials have emerged reporting the efficacy of antimicrobial therapy on cutaneous and pulmonary sarcoidosis. Although the studies are not conclusive, they demonstrate efficacy on endpoints associated with sarcoidosis morbidity and mortality, such as forced vital capacity (FVC).

SARCOIDOSIS EPIDEMIOLOGY SUGGESTS EXPOSURE TO MICROBIAL BIOAEROSOLS

Sarcoidosis is a granulomatous disease of unknown etiology, most commonly involving the lung, skin, lymph node, and eyes.[1] Granulomatous inflammation can be initiated by infectious agents, such as fungi or Mycobacterium tuberculosis (MTB), or by noninfectious agents, such as beryllium (chronic beryllium disease). Analysis of sarcoidosis epidemiology suggests that infectious agents have a role in sarcoidosis pathogenesis. Investigators in A Case Control Etiologic Study of Sarcoidosis observed positive associations between sarcoidosis risk and certain occupations, such as agricultural employment, exposure to insecticides, and moldy environments.[2] Another study noted that the hospitalization admissions for African Americans with sarcoidosis in South Carolina increased with proximity to the Atlantic Ocean.[3] A unifying factor in environmental and geographic reports is the possibility of exposure to microbial bioaerosols. Natural waters; water distribution systems; biofilm in pipes; peat and potting soil; water droplets; equipment, such as bronchoscopes and catheters; and moldy buildings are natural habitats for environmental opportunistic mycobacteria.[4] Aerosolization of environmental opportunistic mycobacteria has been associated with the development of other granulomatous diseases of mycobacterial origin, such as hypersensitivity pneumonitis.[5]

MOLECULAR AND IMMUNOLOGIC INVESTIGATIONS REVEAL MICROBIAL PROTEINS AND DNA

The inability to identify microorganisms by histologic staining or to culture microorganisms from pathologic tissues continues to be one of the strongest arguments against a potential role for infectious agents in sarcoidosis pathogenesis. As molecular analysis continues to grow in sensitivity and specificity, current culture and staining methods are known to identify less than 2% of current microbial communities present within the human biological specimens.[6,7] Advanced molecular techniques, such as deep sequencing technologies, also have demonstrated successful identification of novel microorganisms in pathologic tissues not easily identified by traditional methods.[8,9] Molecular analysis of pathologic tissue for microbial nucleic acids and proteins serves as an alternative means of identifying a putative infectious agent. Polymerase chain reaction (PCR) was used to identify the etiologic agents of Whipple disease (Tropheryma whippelii)[10] as well as the novel coronavirus as the agent of severe acute respiratory syndrome.[11]

A growing scientific interest involves defining the microbial community within distinct diseases, that is, microbiome analysis. Microbiome analysis was performed on the upper and lower airway of subjects with interstitial lung diseases, including idiopathic interstitial pneumonia (IIP), non-IIP, and sarcoidosis as well as Pneumocystis jiroveci pneumonia and healthy controls. The microbiota in lower airways of a majority of patients (30; 90%) primarily consisted of Prevotellaceae, Streptococcaceae, and Acidaminococcaceae; α and β diversity measurements revealed no significant differences in airway microbiota composition between the 5 different groups of patients. It was concluded that IIP, non-IIP, and sarcoidosis are not associated with disordered airway microbiota and a pathogenic role of commensals in the disease process is therefore unlikely.[12] A more targeted molecular approach for microbial pathogens in sarcoidosis granulomas most strongly supports that propionibacteria and/or mycobacteria have a role in sarcoidosis pathogenesis. Japanese researchers report molecular evidence of Propionibacterium acnes DNA in sarcoidosis specimens, although the DNA could also be isolated from control specimens.[13] The distinction lies in the quantitative differences in P acnes DNA between sarcoidosis and controls. The number of genomes of P acnes in BAL cells was correlated with the serum angiotensin-converting enzyme level and the percentage of macrophages in BAL fluid from patients with sarcoidosis. No

significant difference was detected between P granulosum and controls.[14] A murine model of sarcoidosis pathogenesis was successfully developed using heat-killed propionibacteria by intratracheal challenge. This model demonstrated the contribution of Toll-like receptor (TLR)-1, TLR-2, and TLR-9 to the development of the polarized, T_H1 immune response.[15] Another study further confirmed the role of TLR-2 in P acnes–specific sarcoidosis immune responses by demonstrating that P acnes–induced granulomatous pulmonary inflammation was markedly attenuated in TLR-2(−/−) mice compared with wild-type C57BL/6 animals.[16] A recent meta-analysis involving 9 case-control studies of P acnes associated with sarcoidosis revealed a significantly elevated sarcoidosis risk (odds ratio 19.58; 95% CI, 13.06–29.36).[17]

Investigations from independent laboratories worldwide have also reported molecular evidence supporting a significant association between mycobacteria and sarcoidosis. One study reported evidence of mycobacterial 16S ribosomal RNA (rRNA) or RNA polymerase B in 60% of the sarcoidosis granulomas and in none of the controls ($P<.00002$, chi-square).[18] Sequence analysis of the 16S rRNA and rpoB amplicons revealed the presence of a novel Mycobacterium, genetically most similar to MTB complex (99% positional identity). Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Song and colleagues[19] found MTB katG peptides in 75% of sarcoidosis specimens compared with 14% of control specimens ($P = .0006$), in situ hybridization localized MTB katG, and 16S rRNA DNA to the inside of sarcoidosis granulomas. Analysis of Polish sarcoidosis lymph nodes revealed MTB complex heat shock protein (HSP) 70, HSP 65, and HSP 16.[20] Molecular analysis of American sarcoidosis granulomas also revealed the presence of nucleic acids of the mycobacterial virulence factor, superoxide dismutase A (sodA), in 70% of the sarcoidosis specimens compared with 12% of controls ($P = .001$). Sequence analysis of the amplicons demonstrated close positional identity with MTB complex, yet genetically distinct.[21] DNA of mycobacterial HSPs has been detected in cutaneous lesions of Chinese sarcoidosis patients but absent from control specimens. Sequence analysis was consistent with MTB, M chelonae, and M gordonae.[22] Another study reported the ability of real-time PCR analysis to quantitatively differentiate sarcoidosis from tuberculosis using receiver operating characteristic curves.[23] Real-time PCR analysis from these independent laboratories demonstrates that if viable mycobacteria are present within the sarcoidosis

granulomas, they are present below the sensitivity of the acid-fast bacilli histologic stain.[21,23] Future molecular efforts should delineate if the identified nucleic acids or proteins reflect actively replicating organisms or persistent proteins.

IMMUNE RESPONSES AGAINST MYCOBACTERIAL VIRULENCE FACTORS ARE PRESENT IN SYSTEMIC AND ACTIVE SARCOIDOSIS INVOLVEMENT

An equally important modality to delineate if infectious agents have a role in idiopathic disease is to assess for immune responses against microbial proteins. The presence of humoral and cellular responses against microbial antigens is an insightful method for assessing exposure to infectious agents. Increased lymphocyte proliferation induced by *P acnes* has been reported in patients with active sarcoidosis; however, these responses did not correlate with clinical, roentgenographic, physiologic, and BAL findings in regard to disease severity.[24,25] Sarcoidosis T_H1 and T_H17 immune responses against viable *P acnes* that were significantly different from healthy controls were recently reported.[26]

Immune responses against mycobacteria have also been reported. Along with the detection of peptide fragments consistent with katG protein within sarcoidosis granulomas, the existence of humoral immune responses against mycobacterial katG proteins was demonstrated in sarcoidosis patients. Song and colleagues[16] noted IgG antibodies to recombinant MTB katG in sera from 48% of sarcoidosis patients compared with 0% in sera from purified protein derivative–negative controls ($P = .0059$). Sarcoidosis is characterized by polarized CD4+ T cells with a T_H1 immunophenotype. The identification of T_H1 CD4+ cellular immune responses against mycobacterial ESAT-6 and katG peptides in sarcoidosis peripheral blood mononuclear cells (PBMCs) suggested that the sarcoidosis immune response may be against mycobacterial virulence factors.[27] Distinctions in cellular recognition patterns against virulence factors, such as antigen 85A (Ag85A), can differentiate mycobacterial species. For example, patients infected with MTB recognize distinct Ag85A peptides from those infected with *M leprae*.[28] Further investigation of the sarcoidosis immune response pattern against Ag85A confirmed that the pattern detected was distinct from those in patients infected with MTB or *M leprae*.[29] Another report demonstrated systemic CD4+ T_H1 immune responses against multiple mycobacterial virulence factors in sarcoidosis patients. These responses were not only against multiple secreted proteins but also against multiple epitopes within a given protein.[30] These findings are more analogous with what is observed in patients with active bacterial infection.

A dual molecular and immunologic analysis of sarcoidosis specimens for the mycobacterial virulence factor, sodA, demonstrated nucleic acids sequences closest to MTB, yet distinct. Translation of those sequences into peptides to stimulate sarcoidosis PBMC resulted in reproduction of the sarcoidosis T_H1 immunophenotype.[21] Mycobacterial proteins, such as soda, are virulence factors that confer pathogenicity to *Mycobacterium* species.[31] It has been demonstrated that the protein secretion system SecA2 is required for the optimal secretion of sodA and katG. Both of these proteins are synthesized without Sec signal sequences and function to detoxify reactive oxygen intermediates generated by the host macrophage. SecA2 is part of a specialized secretion system that contributes to the virulence of pathogenic mycobacteria by countering the oxidative attack of the host and confers their ability to survive within the host macrophage.[32,33]

In addition, CD4+ and CD8+ T-cell immune responses against MTB katG have been detected in sarcoidosis BAL. Comparison of immune responses to mycobacterial katG whole protein between American and Swedish sarcoidosis subjects revealed no differences despite distinctions in patient phenotypic, genetic, and prognostic characteristics. It was also demonstrated that although T_H1 immune responses were present systemically, katG-reactive CD4+ 1 cells preferentially accumulated in the lung, indicating a compartmentalized response.[34] Patients with or without Löfgren syndrome had similar frequencies of katG-specific interferon-gamma–expressing peripheral T cells. This study also demonstrated that circulating katG-reactive T cells were found in chronic active sarcoidosis but not in patients with inactive disease.[34] The loss of immune responses to mycobacterial virulence factors after resolution of tuberculosis has also been observed.[35] Another report demonstrated that immune responses against these mycobacterial virulence factors are present in sarcoidosis diagnostic BAL and that induction of innate immunity by TLR-2 contributes to the polarized T_H1 immune response. Recognition was significantly absent from BAL fluid cells of patients with other lung diseases, including infectious granulomatous diseases.[36] The detection of immune responses against ESAT-6, katG, and sodA confirms exposure of sarcoidosis patients to a pathogenic mycobacterial species. These proteins are typically secreted during the stage of active

mycobacterial replication, compared with expression of other proteins that are expressed when mycobacteria are in the latent state.[37,38] The immunologic analysis performed to date provides a mechanism for more in-depth analysis of sarcoidosis pathogenesis. These proteins can be used to delineate immunologic pathways that contribute to sarcoidosis resolution or disease progression.

NONINFECTIOUS ETIOLOGIES OF SARCOIDOSIS

It has been reported that the amyloid precursor protein serum amyloid A (SAA) is strikingly abundant in sarcoidosis tissues, predominantly in a nonfibrillar form, and localized to epithelioid granulomas. SAA has been detected in numerous pulmonary infections, such as tuberculosis, nontuberculous mycobacteria infection, and leprosy.[39–42] By comparison, quantitative immunohistochemistry showed that the extent and distribution of SAA in sarcoidosis is significantly lower in other diseases of granulomatous inflammation.[43] Chen and Moller[44] elaborate a concept of chronic stimulation of the innate immune system by disaggregated host protein SAA within granulomas after a microbial infection that induces a hyperimmune T_H1 immune response to microbial antigens in the absence of ongoing infection. SAA levels are reduced in pulmonary tuberculosis subjects after the initiation of antimicrobial therapy.[40] In addition, antibodies against autoantigens, such as zinc finger protein 688 and mitochondrial ribosomal protein L43, have been identified in sarcoidosis BAL and serum. High interindividual heterogeneity was noted.[45] Using pulmonary CD4+ T cells from 16 HLA-DRB1*0301+ patients, HLA-DR molecules were affinity purified and bound peptides acid eluted. The peptides were separated by reversed-phase high-performance liquid chromatography and analyzed by liquid chromatography–mass spectrometry, resulting in the identification of autoantigens, such as vimentin, and ATP synthase.[46] These data support that immune responses against self-antigens are present in local and systemic sites of sarcoidosis subjects.

MICROBIAL INDUCTION OF SARCOIDOSIS CD4+ T-CELL DYSFUNCTION

Investigation of sarcoidosis immune function on T-cell receptor (TCR) stimulation reveals significant distinctions from healthy controls. The presence of chronic immune stimulation due to persistent microbial antigens has been reported to reduce T-cell function. Sarcoidosis T lymphocytes have also been characterized by reduced cytokine expression and proliferative capacity as well as up-regulation of the inhibitory receptor, programmed death-1 (PD-1), all immunologic phenomena associated with elevated antigenic burdens.

As defined by Wherry and colleagues,[47] T-cell exhaustion occurs as a result of chronic antigen stimulation that, over the duration of antigen exposure, results in a gradual reduction in the cell's ability to optimally respond to TCR stimulation. As such, although healthy T cells produce high levels of cytokine and exhibit high levels of proliferation and low levels of apoptosis in response to antigen, exhausted T cells gradually lose these normal functions until they can no longer respond to antigen and instead undergo apoptosis on TCR activation. PD-1 up-regulation on T cells plays a significant role in acquisition of the exhaustion phenotype. As an inhibitory coreceptor, signaling between PD-1 and its ligands, PDL1 and PDL2, functions to modulate tolerance to self antigens and limit the robustness of the adaptive immune response to foreign antigens. Exhausted T cells express high levels of PD-1 that correlates well with the systematic loss of cellular function. Recent findings that PD-1 is up-regulated on dysfunctional sarcoidosis T cells as well as the T cells of other granulomatous diseases characterized by microbial antigens, such as MTB[48–50] and schistosomiasis,[51] suggest that this phenotype could result from persistent antigen exposure (**Fig. 1**, **Table 1**).

Up-regulation of the PD-1 receptor and reduced proliferative capacity in sarcoidosis BAL and peripheral CD4+ T cells were recently reported.[52] Restoration of sarcoidosis CD4+ T-cell proliferative capacity to healthy control levels was apparent after PD-1 pathway blockade.[52] Various mechanisms by which PD-1 interferes with T-cell proliferation have been well described. PD-1 has been reported to inhibit CD4+ T-cell proliferation by blocking cell cycle progression through the suppression of Skp2 transcription.[53,54] Skp2 is the substrate recognition component of the ubiquitin ligase complex SCF^{Skp2} that binds to and degrades p27^{kip1}, a cyclin-dependent kinase (CDK) inhibitor, thereby allowing continuation of the cell cycle. PD-1 cell cycle impediment and, therefore, proliferation hindrance have been shown to be the result of PI3K/Akt and ERK pathway inactivation.[53,54] PD-1 inhibition of T-cell proliferation has been correlated with increased p27 availability and repression of Cdc25A, a CDK-activating phosphatase.[53,54] PD-1 engagement has also been demonstrated to attenuate TCR signaling by preventing ZAP70 and PKCθ activation.[55]

Fig. 1. PD-1 inhibits sarcoidosis cellular proliferation. High antigenic loads induce PD-1 up-regulation, which alters cell cycle progression. Cell cycle progression is necessary for normal CD4$^+$ T-cell proliferation to clear microbial or autoantigens, thus leading to clinical resolution. Persistent antigen further PD-1 up-regulation and loss of cellular function.

The reported up-regulation of PD-1 is particularly important because it has been associated with the emergence of human lymphotropic viruses, such as Epstein-Barr virus and cytomegalovirus.[56–58] These same viruses have been associated with sarcoidosis pathogenesis.[59,60]

CLINICAL TRIALS OF ANTIMICROBIAL THERAPY IN SARCOIDOSIS

After the publication of molecular and immunologic support for a role of microorganisms in sarcoidosis pathogenesis, such as fungi, propionibacteria, and mycobacteria, there has been an increasing number of case reports and clinical trials regarding efficacy with antimicrobial therapy. Numerous prior reports of the tetracyclines, in particular, doxycycline and minocycline, have been published in subjects with cutaneous sarcoidosis.[61–63] Although minocycline has antimicrobial effects against *P acnes*, its mechanism of

action is thought immunomodulatory.[64] A recent report of the efficacy of clarithromycin, which has efficacy against propionibacteria and mycobacteria, was reported in a Japanese woman with systemic sarcoidosis.[65] Conclusive delineation of the mechanism of action is pending.

Fungal antigens are also reported to contribute to sarcoidosis pathogenesis.[66] Clinical and radiographic improvement after administration of antifungal therapy, such as posaconazole (300 mg/d) or ketoconazole (200 mg/d) with or without corticosteroids, has been reported in Slovenian sarcoidosis patients. The investigators conducted an open-labelled, patient-preference trial of steroids (methylprednisolone 0.4 mg/kg, antifungal agents (posaconazole 300 mg/d or ketoconazole 200 mg/d), or steroids/antifungal agents. The most significant clinical radiographic improvement was detected in the antifungal group; they also reported a reduction in disease recurrence among those on antifungal therapy. Study limitations include the lack of randomization as well as not being conducted in a double-blind fashion.

Two clinical trials regarding the efficacy of antimycobacterial therapy in sarcoidosis pathogenesis have been reported. A double blind, placebo-controlled investigation of an antimycobacterial regimen consisting of concomitant levofloxacin, ethambutol, azithromycin and rifampin (CLEAR) compared with placebo was conducted in subjects with cutaneous sarcoidosis. In the intention-to-treat analysis, the CLEAR-treated group had a mean (SD) decrease in lesion diameter of −8.4 (14.0) mm compared with an increase of 0.07 (3.2) mm in the placebo-treated group

Table 1
Evidence for etiologic agents in sarcoidosis pathogenesis

Etiology	Evidence
Mycobacteria	M, I, E[18–22,27,29,30]
Propionibacteria	M, I[13–15,24–26]
Fungal antigens	M[66]
Autoantigens	M, I[45,46]

Abbreviations: E, epidemiologic; I, immunologic; M, molecular.

(P = .05). The CLEAR group had a significant reduction in granuloma burden and experienced a mean (SD) decline of −2.9 (2.5) mm in lesion severity compared with a decline of −0.6 (2.1) mm in the placebo group (P = .02). The observed clinical reductions were present at the 180-day follow-up period. Transcriptome analysis of sarcoidosis CD4[+] T cells revealed reversal of pathways associated with disease severity and enhanced T-cell function after TCR stimulation.[67]

In addition, an open-label investigation of this same regimen was conducted in pulmonary sarcoidosis subjects; 15 chronic, pulmonary sarcoidosis patients with FVCs between 45% and 80% of predicted were enrolled. The primary efficacy endpoint was change in absolute FVC from baseline to completion of therapy. Secondary endpoints were change in functional capacity measured by Six Minute Walk Distance (6MWD) and quality-of-life assessment measured by St. George's Respiratory Questionnaire (SGRQ). Of 15 patients enrolled, 11 completed 4 weeks of therapy, and 8 completed 8 weeks of therapy. The CLEAR regimen was associated with an FVC increase of 0.23 L at 4 weeks and 0.42 L at 8 weeks (P = .0098 and 0.016, respectively). The 6MWD increased by 87 m from baseline to 8 weeks (P = .0078). The mean score of the validated SGRQ was improved at 8 weeks over baseline (P = .023).[68]

These early trials are promising. Future investigation of the mechanisms by which the antimicrobials work—as antimicrobials, immune modulators, or both—is warranted.

SUMMARY

Recent molecular, genetic, and immunologic studies from independent laboratories support an association with sarcoidosis and microbial antigens, particularly mycobacteria or propionibacteria. The findings among American sarcoidosis subjects are most strongly associated with mycobacteria and, among Japanese sarcoidosis subjects, propionibacteria. Because epidemiologic studies indicate that both sarcoidosis morbidity and mortality is increasing,[69] the impetus on current sarcoidosis researchers is to translate their strong basic research investigations into innovative therapeutics that will have an impact on sarcoidosis pathogenesis and hopefully lead to a cure. The progress to date strongly supports advances toward this goal.

REFERENCES

1. Baughman RP. Sarcoidosis. Clin Dermatol 2007; 25(3):231.

2. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004;170(12):1324–30.

3. Kajdasz DK, Judson MA, Mohr LC Jr, et al. Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators. Am J Epidemiol 1999;150(3):271–8.

4. Falkinham JO III. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002;23(3): 529–51.

5. Hanak V, Kalra S, Aksamit TR, et al. Hot tub lung: presenting features and clinical course of 21 patients. Respir Med 2006;100(4):610–5.

6. DiGiulio DB, Romero R, Amogan HP, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One 2008;3(8):e3056.

7. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A 2006;103(3):732–7.

8. Whitley R. The new age of molecular diagnostics for microbial agents. N Engl J Med 2008;358(10): 988–9.

9. Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008;358(10):991–8.

10. Relman DA, Schmidt TM, MacDermott RP, et al. Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 1992;327(5):293–301.

11. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348(20): 1953–66.

12. Garzoni C, Brugger SD, Qi W, et al. Microbial communities in the respiratory tract of patients with interstitial lung disease. Thorax 2013;68(12):1150–6.

13. Ishige I, Eishi Y, Takemura T, et al. Propionibacterium acnes is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22(1):33–42.

14. Ichikawa H, Kataoka M, Hiramatsu J, et al. Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2008;25(1):15–20.

15. McCaskill JG, Chason KD, Hua X, et al. Pulmonary immune responses to Propionibacterium acnes in C57BL/6 and BALB/c mice. Am J Respir Cell Mol Biol 2006;35(3):347–56.

16. Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005;201:755–67.

17. Zhou Y, Hu Y, Li H. Role of propionibacterium acnes in sarcoidosis: a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis 2013;30(4):262–7.

18. Drake WP, Pei Z, Pride DT, et al. Molecular analysis of sarcoidosis tissues for mycobacterium species DNA. Emerg Infect Dis 2002;8(11):1334–41.

19. Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005;201(5):755–67.

20. Dubaniewicz A, Dubaniewicz-Wybieralska M, Sternau A, et al. Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J Clin Microbiol 2006;44(9):3448–51.

21. Allen SS, Evans W, Carlisle J, et al. Superoxide dismutase A antigens derived from molecular analysis of sarcoidosis granulomas elicit systemic Th-1 immune responses. Respir Res 2008;9:36.

22. Ding XL, Cai L, Zhang JZ. Detection and identification of mycobacterial gene in skin lesions and lymph nodes in patients with sarcoidosis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2009;31(1):20–3 [in Chinese].

23. Zhou Y, Li HP, Li QH, et al. Differentiation of sarcoidosis from tuberculosis using real-time PCR assay for the detection and quantification of Mycobacterium tuberculosis. Sarcoidosis Vasc Diffuse Lung Dis 2008;25(2):93–9.

24. Nakata Y, Ejiri T, Kishi T, et al. Alveolar lymphocyte proliferation induced by Propionibacterium acnes in sarcoidosis patients. Acta Med Okayama 1986;40(5):257–64.

25. Nakata Y, Ejiri T, Kishi T, et al. Alveolar lymphocyte proliferation in sarcoidosis patients induced by Propionibacterium acnes. Nihon Kyobu Shikkan Gakkai Zasshi 1985;23(4):413–9 [in Japanese].

26. Furusawa H, Suzuki Y, Miyazaki Y, et al. Th1 and Th17 immune responses to viable Propionibacterium acnes in patients with sarcoidosis. Respir Investig 2012;50(3):104–9.

27. Drake WP, Dhason MS, Nadaf M, et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun 2007;75(1):527–30.

28. Launois P, DeLeys R, Niang MN, et al. T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect Immun 1994;62(9):3679–87.

29. Hajizadeh R, Sato H, Carlisle J, et al. Mycobacterium tuberculosis antigen 85A induces Th-1 immune responses in systemic sarcoidosis. J Clin Immunol 2007;27(4):445–54.

30. Carlisle J, Evans W, Hajizadeh R, et al. Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells. Clin Exp Immunol 2007;150(3):460–8.

31. Edwards KM, Cynamon MH, Voladri RK, et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2001;164(12):2213–9.

32. Rigel NW, Gibbons HS, McCann JR, et al. The accessory SecA2 system of mycobacteria requires ATP binding and the canonical SecA1. J Biol Chem 2009;284(15):9927–36.

33. Braunstein M, Espinosa BJ, Chan J, et al. SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis. Mol Microbiol 2003;48(2):453–64.

34. Chen ES, Wahlstrom J, Song Z, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008;181(12):8784–96.

35. Pathan AA, Wilkinson KA, Klenerman P, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001;167(9):5217–25.

36. Oswald-Richter KA, Culver DA, Hawkins C, et al. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun 2009;77(9):3740–8.

37. Andersen P. The T cell response to secreted antigens of Mycobacterium tuberculosis. Immunobiology 1994;191(4–5):537–47.

38. Andersen P, Askgaard D, Ljungqvist L, et al. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 1991;59(4):1558–63.

39. Essone PN, Chegou NN, Loxton AG, et al. Host cytokine responses induced after overnight stimulation with novel M. tuberculosis infection phase-dependent antigens show promise as diagnostic candidates for TB disease. PLoS One 2014;9(7):e102584.

40. de Beer FC, Nel AE, Gie RP, et al. Serum amyloid A protein and C-reactive protein levels in pulmonary tuberculosis: relationship to amyloidosis. Thorax 1984;39(3):196–200.

41. Shinozuka N, Kasamatsu N, Seto T, et al. A fatal case of pulmonary non-tuberculous mycobacteriosis with reactive AA amyloidosis. Nihon Kokyuki Gakkai Zasshi 2007;45(8):636–42 [in Japanese].

42. McAdam KP, Foss NT, Garcia C, et al. Amyloidosis and the serum amyloid A protein response to muramyl dipeptide analogs and different mycobacterial species. Infect Immun 1983;39(3):1147–54.

43. Chen ES, Moller DR. Etiologic role of infectious agents. Semin Respir Crit Care Med 2014;35(3):285–95.

44. Chen ES, Moller DR. Etiologies of sarcoidosis. Clin Rev Allergy Immunol 2015;49(1):6–18.

45. Haggmark A, Hamsten C, Wiklundh E, et al. Proteomic profiling reveals autoimmune targets in sarcoidosis. Am J Respir Crit Care Med 2015;191(5):574–83.

46. Wahlstrom J, Dengjel J, Persson B, et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest 2007;117(11):3576–82.

47. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12(6):492–9.

48. Singh A, Dey AB, Mohan A, et al. Programmed death-1 receptor suppresses gamma-IFN producing NKT cells in human tuberculosis. Tuberculosis (Edinb) 2014;94(3):197–206.

49. Singh A, Mohan A, Dey AB, et al. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis 2013;208(4):603–15.

50. Henao-Tamayo M, Irwin SM, Shang S, et al. T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis. Tuberculosis (Edinb) 2011;91(4):308–13.

51. Colley DG, Sasser LE, Reed AM. PD-L2+ dendritic cells and PD-1+ CD4+ T cells in schistosomiasis correlate with morbidity. Parasite Immunol 2005; 27(1–2):45–53.

52. Braun NA, Celada LJ, Herazo-Maya JD, et al. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Am J Respir Crit Care Med 2014;190(5):560–71.

53. Patsoukis N, Sari D, Boussiotis VA. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle 2012;11(23): 4305–9.

54. Patsoukis N, Brown J, Petkova V, et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal 2012;5(230):ra46.

55. Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004;574(1–3):37–41.

56. Kato T, Nishida T, Ito Y, et al. Correlations of programmed death 1 expression and serum IL-6 level with exhaustion of cytomegalovirus-specific T cells after allogeneic hematopoietic stem cell transplantation. Cell Immunol 2014;288(1–2):53–9.

57. Dirks J, Tas H, Schmidt T, et al. PD-1 analysis on CD28(-) CD27(-) CD4 T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients. Am J Transplant 2013; 13(12):3132–41.

58. Sester U, Presser D, Dirks J, et al. PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008;8(7):1486–97.

59. Yonemaru M, Kasuga I, Kusumoto H, et al. Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur Respir J 1997; 10(9):2040–5.

60. Rottoli P, Bianchi Bandinelli ML, Rottoli L, et al. Sarcoidosis and infections by human lymphotropic viruses. Sarcoidosis 1990;7(1):31–3.

61. Sheu J, Saavedra AP, Mostaghimi A. Rapid response of tattoo-associated cutaneous sarcoidosis to minocycline: case report and review of the literature. Dermatol Online J 2014;20(8):1–5.

62. Steen T, English JC. Oral minocycline in treatment of cutaneous sarcoidosis. JAMA Dermatol 2013; 149(6):758–60.

63. Baba K, Yamaguchi E, Matsui S, et al. A case of sarcoidosis with multiple endobronchial mass lesions that disappeared with antibiotics. Sarcoidosis Vasc Diffuse Lung Dis 2006;23(1):78–9.

64. Miyazaki E, Ando M, Fukami T, et al. Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect? Clin Rheumatol 2008;27(9):1195–7.

65. Takemori N, Nakamura M, Kojima M, et al. Successful treatment in a case of propionibacterium acnes-associated sarcoidosis with clarithromycin administration: a case report. J Med Case Rep 2014;8:15.

66. Tercelj M, Stopinsek S, Ihan A, et al. In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis. Clin Exp Immunol 2011;166(1):87–93.

67. Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol 2013; 149(9):1040–9.

68. Drake W, Richmond BW, Oswald-Richter K, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2013;30(3):201–11.

69. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011;183(11): 1524–30.